Rachelle Suzanne Jacques - 01 Jan 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Chief Executive Officer, Director
Signature: /s/ Rachelle Jacques
Issuer symbol: AKTX
Transactions as of: 01 Jan 2024
Net transactions value: $0
Form type: 3
Filing time: 02 Jan 2024, 20:06:13 UTC
Previous filing: 20 Jun 2023
Next filing: 30 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	AKTX	Ordinary Shares, par value $0.0001 per share						538,457,900	01 Jan 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AKTX	Stock Option (Right to Buy)							01 Jan 2024	Ordinary Shares, par value $0.0001 per share	207,634,400	$0.0124	Direct	F2
holding	AKTX	Stock Option (Right to Buy)							01 Jan 2024	Ordinary Shares, par value $0.0001 per share	29,762,300	$0.0124	Direct	F2
holding	AKTX	Stock Option (Right to Buy)							01 Jan 2024	Ordinary Shares, par value $0.0001 per share	152,690,700	$0.001600	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Securities beneficially owned totaling 538,457,900 includes 153,397,775 ordinary shares, par value $0.0001per share ("Ordinary Shares") owned and 385,060,125 of unvested time-based restricted stock units held by the Reporting Person.
F2	The stock option award was granted under the Issuer's 2014 Equity Incentive Plan (the "2014 Plan"). The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on March 28, 2022, subject to continued service with the Issuer.
F3	The stock option award was granted under the Issuer's 2014 Plan. The stock option vests and becomes exercisable ratably on a semiannual basis over a four-year period commencing on June 1, 2023, subject to continued service with the Issuer.